Antisaccade Latency Is Sensitive to Longitudinal Change of Motor and Cognitive Symptoms in Parkinson's Disease

Considerable efforts have been made to evaluate different aspects of saccadic eye movements as potential biomarkers in Parkinson's disease (PD).The antisaccade task is a widely used FIG. 1. Findings during the levodopa (L-dopa) challenge test.A drug challenge test was arranged to characterize the nature of the patient's disabling dyskinesia.The patient was given 500 mg oral L-dopa and was monitored closely throughout one dosing cycle.The temporal and topographic pattern of her dyskinesia is characteristic of diphasic dyskinesia in advanced Parkinson's disease.Inhaled L-dopa was explored to address her wearing-off, but we also observed an improvement and shortened duration of her diphasic dyskinesia.*Compared to the baseline/off state.A, amantadine; E, entacapone; IL, inhaled L-dopa; L, L-dopa; LED, L-dopa equivalent dose; MDS-UPDRS, Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS).[Color figure can be viewed at wileyonlinelibrary.com]